InterPAD - DETAILS

Ro 48-8071, 161582-11-2, [4-({6-[allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, Ro-48-8071, Ro48-8071, YDR69X9Q9M, R048-8071, (4-bromophenyl)-[2-fluoro-4-[6-[methyl(prop-2-enyl)amino]hexoxy]phenyl]methanone, CHEMBL304858, (4-BROMOPHENYL)[3-FLUORO-4-[[6-(METHYL-2-PROPENYLAMINO)HEXYL]OXY]PHENYL]-METHANONE, 1gsz, (4-bromophenyl)[2-fluoro-4-({6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy)phenyl]methanone, (4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl)-(4-bromo-phenyl)-methanone, [4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]-(4-bromo-phenyl)-methanone, {4-[6-(Allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-bromo-phenyl)-methanone, compound 2 [PMID: 22533316], Methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propenylamino)hexyl]oxy]phenyl]-,(2E)-2-butenedioate, UNII-YDR69X9Q9M, (4'-(6-Allylmethylaminohexyloxy)-2'-fluorophenyl)-4-(4-bromophenyl)methanone fumarate, GTPL6710, SCHEMBL3674881, DTXSID90870077, CHEBI:101064, CMYCCJYVZIMDFU-UHFFFAOYSA-N, HMS3649J22, HMS3743C21, BCP30557, BDBM50128065, AKOS025294639, CS-3518, DB02016, NCGC00165878-01, NCGC00165878-02, HY-18630, NS00018037, SR-01000946731, J-009841, SR-01000946731-1, Q27088590, N-allyl-6-(4-(4-bromobenzoyl)-3-fluorophenoxy)-N-methylhexan-1-aminium, (4-bromophenyl)-[2-fluoro-4-[6-(methyl-prop-2-enylamino)hexoxy]phenyl]methanone, (4-Bromophenyl)[2-fluoro-4-[[6-(methyl-2-propenylamino)hexyl]oxy]phenyl]methanone, [4-[6-[allyl(methyl)amino]hexoxy]-2-fluoro-phenyl]-(4-bromophenyl)methanone, Methanone, (4-bromophenyl)(2-fluoro-4-((6-(methyl-2-propenylamino)hexyl)oxy)phenyl)-, Methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]phenyl]-, Ro 488071; Ro488071; Ro-488071; Ro 488071; Ro-488071

No.	Title	Href
1	The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. Breast Cancer Res Treat. 2022 Feb;192(1):53-63. doi: 10.1007/s10549-021-06487-y.	`Click`

No.

Title

Href

The estrogen receptor beta agonist liquiritigenin enhances the inhibitory effects of the cholesterol biosynthesis inhibitor RO 48-8071 on hormone-dependent breast-cancer growth. Breast Cancer Res Treat. 2022 Feb;192(1):53-63. doi: 10.1007/s10549-021-06487-y.

Click

Name	[4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone
PubChem CID	1949
Molecular Weight	448.4g/mol
Synonyms	Ro 48-8071, 161582-11-2, [4-({6-[allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone, Ro-48-8071, Ro48-8071, YDR69X9Q9M, R048-8071, (4-bromophenyl)-[2-fluoro-4-[6-[methyl(prop-2-enyl)amino]hexoxy]phenyl]methanone, CHEMBL304858, (4-BROMOPHENYL)[3-FLUORO-4-[[6-(METHYL-2-PROPENYLAMINO)HEXYL]OXY]PHENYL]-METHANONE, 1gsz, (4-bromophenyl)[2-fluoro-4-({6-[methyl(prop-2-en-1-yl)amino]hexyl}oxy)phenyl]methanone, (4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl)-(4-bromo-phenyl)-methanone, [4-[6-(allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl]-(4-bromo-phenyl)-methanone, {4-[6-(Allyl-methyl-amino)-hexyloxy]-2-fluoro-phenyl}-(4-bromo-phenyl)-methanone, compound 2 [PMID: 22533316], Methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propenylamino)hexyl]oxy]phenyl]-,(2E)-2-butenedioate, UNII-YDR69X9Q9M, (4'-(6-Allylmethylaminohexyloxy)-2'-fluorophenyl)-4-(4-bromophenyl)methanone fumarate, GTPL6710, SCHEMBL3674881, DTXSID90870077, CHEBI:101064, CMYCCJYVZIMDFU-UHFFFAOYSA-N, HMS3649J22, HMS3743C21, BCP30557, BDBM50128065, AKOS025294639, CS-3518, DB02016, NCGC00165878-01, NCGC00165878-02, HY-18630, NS00018037, SR-01000946731, J-009841, SR-01000946731-1, Q27088590, N-allyl-6-(4-(4-bromobenzoyl)-3-fluorophenoxy)-N-methylhexan-1-aminium, (4-bromophenyl)-[2-fluoro-4-[6-(methyl-prop-2-enylamino)hexoxy]phenyl]methanone, (4-Bromophenyl)[2-fluoro-4-[[6-(methyl-2-propenylamino)hexyl]oxy]phenyl]methanone, [4-[6-[allyl(methyl)amino]hexoxy]-2-fluoro-phenyl]-(4-bromophenyl)methanone, Methanone, (4-bromophenyl)(2-fluoro-4-((6-(methyl-2-propenylamino)hexyl)oxy)phenyl)-, Methanone, (4-bromophenyl)[2-fluoro-4-[[6-(methyl-2-propen-1-ylamino)hexyl]oxy]phenyl]-, Ro 488071; Ro488071; Ro-488071; Ro 488071; Ro-488071
Drug Type	Not Available
Formula	C₂₃H₂₇BrFNO₂
SMILES	CN(CCCCCCOC1=CC(=C(C=C1)C(=O)C2=CC=C(C=C2)Br)F)CC=C
InChI	1S/C23H27BrFNO2/c1-3-14-26(2)15-6-4-5-7-16-28-20-12-13-21(22(25)17-20)23(27)18-8-10-19(24)11-9-18/h3,8-13,17H,1,4-7,14-16H2,2H3
InChIKey	CMYCCJYVZIMDFU-UHFFFAOYSA-N
CAS Number	161582-11-2
ChEMBL ID	CHEMBL304858
ChEBI ID	CHEBI:101064
Drug Bank ID	DB02016
Toxicity	Organism	Test Type	Route(Dose)
Structure			Download 2D MOL 3D MOL

Pair Name	Liquiritigenin, [4-({6-[Allyl(methyl)amino]hexyl}oxy)-2-fluorophenyl](4-bromophenyl)methanone
Partner Name	Liquiritigenin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Gene Regulation	Up-regulation	Expression	ESR2	hsa2100
Gene Regulation	Down-regulation	Expression	VEGFA	hsa7422
In Vitro Model	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
In Vitro Model	BT-474	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0179
Result	The ERβ ligand LQ significantly enhanced the inhibition of breast-cancer cell viability and tumor-xenograft growth by RO. The anti-tumor properties of RO may in part be due to an off-target effect that reduces ERα and increases ERβ, the latter of which can then interact with LQ to promote anti-proliferative effects. The RO + LQ combination may have value when considering novel treatment strategies for hormone-dependent breast cancer.